{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:30:27Z","timestamp":1792553427658,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ejca.2016.02.010","type":"journal-article","created":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T05:01:05Z","timestamp":1459486865000},"page":"12-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":361,"special_numbering":"C","title":["Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor"],"prefix":"10.1016","volume":"60","author":[{"given":"V.R.","family":"Belum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Benhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Postow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.H.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"Busam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Wolchok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2016.02.010_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1189\/jlb.1212631","article-title":"At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy","volume":"94","author":"Callahan","year":"2013","journal-title":"J Leukoc Biol"},{"issue":"7","key":"10.1016\/j.ejca.2016.02.010_bib2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.ejca.2016.02.010_bib3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2016.02.010_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"issue":"13","key":"10.1016\/j.ejca.2016.02.010_bib5","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2016.02.010_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrclinonc.2013.245","article-title":"Mitigating the toxic effects of anticancer immunotherapy","volume":"11","author":"Gangadhar","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2016.02.010_bib7","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2016.02.010_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2016.02.010_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ejca.2016.02.010_bib10","series-title":"Pembrolizumab [package insert]","year":"2015"},{"key":"10.1016\/j.ejca.2016.02.010_bib11","series-title":"Nivolumab [package insert]","year":"2015"},{"key":"10.1016\/j.ejca.2016.02.010_bib12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2016.02.010_bib13","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2016.02.010_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2016.02.010_bib15","unstructured":"National Cancer Institute [Internet]. Bethesda: The Organization; [webpage last updated 2015 Jun 8; cited 2015 Dec 18]. Cancer Therapy Evaluation Program: Protocol Development. Available from: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"10.1016\/j.ejca.2016.02.010_bib16","article-title":"Comprehensive meta-analysis version 2","author":"Borenstein","year":"2005","journal-title":"Biostat, Englewood NJ"},{"key":"10.1016\/j.ejca.2016.02.010_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ejca.2016.02.010_bib18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","article-title":"Quantitative synthesis in systematic reviews","volume":"127","author":"Lau","year":"1997","journal-title":"Ann Intern Med"},{"issue":"26","key":"10.1016\/j.ejca.2016.02.010_bib19","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.ejca.2016.02.010_bib20","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2016.02.010_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2016.02.010_bib22","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-pd-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2016.02.010_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2016.02.010_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2016.02.010_bib25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2016.02.010_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"issue":"9948","key":"10.1016\/j.ejca.2016.02.010_bib27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ejca.2016.02.010_bib28","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2016.02.010_bib29","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"15 Suppl.","key":"10.1016\/j.ejca.2016.02.010_bib30","first-page":"e20088","article-title":"A single-institution experience with the pembrolizumab (PEM) Expanded Access Program (EAP)","volume":"33","author":"Perdon","year":"2015","journal-title":"ASCO Meet Abstr"},{"issue":"13","key":"10.1016\/j.ejca.2016.02.010_bib31","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2016.02.010_bib32","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2016.02.010_bib33","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2016.02.010_bib34","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archderm.142.2.166","article-title":"Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent","volume":"142","author":"Jaber","year":"2006","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.ejca.2016.02.010_bib35","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.ejca.2016.02.010_bib36","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","article-title":"Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival","volume":"24","author":"Delyon","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2016.02.010_bib37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","article-title":"Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2016.02.010_bib38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdermsci.2015.03.001","article-title":"Clinical perspectives and murine models of lichenoid tissue reaction\/interface dermatitis","volume":"78","author":"Okiyama","year":"2015","journal-title":"J Dermatol Sci"},{"issue":"7","key":"10.1016\/j.ejca.2016.02.010_bib39","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamadermatol.2015.0249","article-title":"Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma","volume":"151","author":"Ohtsuka","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"16","key":"10.1016\/j.ejca.2016.02.010_bib40","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non \u2013small-cell lung cancer","volume":"22","author":"P\u00e9rez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2016.02.010_bib41","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/annonc\/mds145","article-title":"Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study","volume":"23","author":"Poprach","year":"2012","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2016.02.010_bib42","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1200\/JCO.2001.19.15.3477","article-title":"Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma","volume":"19","author":"Phan","year":"2001","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ejca.2016.02.010_bib43","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"issue":"22 Pt 1","key":"10.1016\/j.ejca.2016.02.010_bib44","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2016.02.010_bib45","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"issue":"15 Suppl.","key":"10.1016\/j.ejca.2016.02.010_bib46","first-page":"9028","article-title":"Nivolumab in resected and unresectable melanoma: immune-related adverse events and association with survival outcomes","volume":"33","author":"Freeman-Keller","year":"2015","journal-title":"ASCO Meet Abstr"},{"issue":"7","key":"10.1016\/j.ejca.2016.02.010_bib47","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2016.02.010_bib48","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archinternmed.2009.306","article-title":"Reporting of safety results in published reports of randomized controlled trials","volume":"169","author":"Pitrou","year":"2009","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.ejca.2016.02.010_bib49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2010.31.9624","article-title":"Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials","volume":"29","author":"Seruga","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916001258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916001258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T01:10:11Z","timestamp":1668733811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804916001258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":49,"alternative-id":["S0959804916001258"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.02.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}